Interleukin-6 as a Therapeutic Target on inflammatory disease and Castleman's disease
详细信息 查看官网全文
- 英文论文题名：Interleukin-6 as a Therapeutic Target on inflammatory disease and Castleman's disease
- 论文作者：Wang Yue ; Yu Bo
- 英文论文作者：Wang Yue ; Yu Bo ; Logistics College of Chinese People's Armed Police Forces
- 年：2016
- 作者机构：Logistics College of Chinese People's Armed Police Forces;
- 英文论文关键词：IL-6 ; Inflammatory disease ; Castleman disease
- 会议召开时间：2016-11-04
- 会议录名称：第十一届全国免疫学学术大会摘要汇编
- 英文会议录名称：Abstracts of 2016 CSI Congress on Immunology
- 语种：英文
- 分类号：R593.2
- 学会代码：IGMD
- 会议名称：第十一届全国免疫学学术大会
- 会议地点：中国安徽合肥
- 主办单位：中国免疫学会
- 学会名称：中国免疫学会
- 页数：1
- 文件大小：1012k
- 原文格式：D
- 会议级别：全国
摘要
Objective: Human Interleukin-6(IL-6) is a cytokine produced by many cell types, including stromal cells, hematopoietic cells, epithelial cells, or muscle cells, that has pleiotropic effects. IL-6 acts through a hexametric receptor, which contains the ligand-binding IL-6 receptor α chain and the common cytokine receptor signal-transducing subunit gp130. The binding of IL-6 to gp130 activates multiple signal transduction pathways such as JAK/STATs, MEK/ERK and PI3K/Akt pathways. Methods: Anti-IL-6 therapy reduces inflammation, hepatic acute phase proteins, and anemia and has antiangiogenic effects. Castleman disease is a lymphoproliferative disease characterized by benign hyperplastic lymph nodes, follicular hyperplasia with polyclonal plasmablastic proliferation and capillary proliferation associated with vascular hyperplasia and high IL-6 activity, mainly due to viral IL-6. Results: Blocking IL-6 has demonstrated therapeutic efficacy with drug registration in Castleman disease and inflammatory disease such as rheumatoid arthritis or Crohn disease without major toxicity. Interestingly, the inhibition of C-reactive protein(CRP) production is a trustworthy surrogate marker of anti-IL-6 therapy efficacy. Clinically registered IL-6 inhibitors include siltuximab, an anti-IL-6 m Ab, and tocilizumab, an anti-IL-6 receptor m Ab. Sirukumab, a humanized antiIL-6 m Ab, has been assayed in healthy subjects to determine PK/PD and safety. Sant7, a potent antagonist of the IL-6 receptor, was engineered through targeted amino acid substitutions in key residues of the human IL-6 molecule. Conclusion: Anti-IL-6 theraprutics are able to neutralize IL-6 production in vivo and are safe and useful in inflammatory disease and Castleman disease.
Objective: Human Interleukin-6(IL-6) is a cytokine produced by many cell types, including stromal cells, hematopoietic cells, epithelial cells, or muscle cells, that has pleiotropic effects. IL-6 acts through a hexametric receptor, which contains the ligand-binding IL-6 receptor α chain and the common cytokine receptor signal-transducing subunit gp130. The binding of IL-6 to gp130 activates multiple signal transduction pathways such as JAK/STATs, MEK/ERK and PI3K/Akt pathways. Methods: Anti-IL-6 therapy reduces inflammation, hepatic acute phase proteins, and anemia and has antiangiogenic effects. Castleman disease is a lymphoproliferative disease characterized by benign hyperplastic lymph nodes, follicular hyperplasia with polyclonal plasmablastic proliferation and capillary proliferation associated with vascular hyperplasia and high IL-6 activity, mainly due to viral IL-6. Results: Blocking IL-6 has demonstrated therapeutic efficacy with drug registration in Castleman disease and inflammatory disease such as rheumatoid arthritis or Crohn disease without major toxicity. Interestingly, the inhibition of C-reactive protein(CRP) production is a trustworthy surrogate marker of anti-IL-6 therapy efficacy. Clinically registered IL-6 inhibitors include siltuximab, an anti-IL-6 m Ab, and tocilizumab, an anti-IL-6 receptor m Ab. Sirukumab, a humanized antiIL-6 m Ab, has been assayed in healthy subjects to determine PK/PD and safety. Sant7, a potent antagonist of the IL-6 receptor, was engineered through targeted amino acid substitutions in key residues of the human IL-6 molecule. Conclusion: Anti-IL-6 theraprutics are able to neutralize IL-6 production in vivo and are safe and useful in inflammatory disease and Castleman disease.
Objective: Human Interleukin-6(IL-6) is a cytokine produced by many cell types, including stromal cells, hematopoietic cells, epithelial cells, or muscle cells, that has pleiotropic effects. IL-6 acts through a hexametric receptor, which contains the ligand-binding IL-6 receptor α chain and the common cytokine receptor signal-transducing subunit gp130. The binding of IL-6 to gp130 activates multiple signal transduction pathways such as JAK/STATs, MEK/ERK and PI3K/Akt pathways. Methods: Anti-IL-6 therapy reduces inflammation, hepatic acute phase proteins, and anemia and has antiangiogenic effects. Castleman disease is a lymphoproliferative disease characterized by benign hyperplastic lymph nodes, follicular hyperplasia with polyclonal plasmablastic proliferation and capillary proliferation associated with vascular hyperplasia and high IL-6 activity, mainly due to viral IL-6. Results: Blocking IL-6 has demonstrated therapeutic efficacy with drug registration in Castleman disease and inflammatory disease such as rheumatoid arthritis or Crohn disease without major toxicity. Interestingly, the inhibition of C-reactive protein(CRP) production is a trustworthy surrogate marker of anti-IL-6 therapy efficacy. Clinically registered IL-6 inhibitors include siltuximab, an anti-IL-6 m Ab, and tocilizumab, an anti-IL-6 receptor m Ab. Sirukumab, a humanized antiIL-6 m Ab, has been assayed in healthy subjects to determine PK/PD and safety. Sant7, a potent antagonist of the IL-6 receptor, was engineered through targeted amino acid substitutions in key residues of the human IL-6 molecule. Conclusion: Anti-IL-6 theraprutics are able to neutralize IL-6 production in vivo and are safe and useful in inflammatory disease and Castleman disease.
引文